Vivos Therapeutics (VVOS) Net Cash Flow (2020 - 2026)

Vivos Therapeutics (VVOS) has reported Net Cash Flow for 7 consecutive years, with -$378000.0 the latest figure, recorded in Q2 2026.

• On a quarterly basis, Net Cash Flow rose 95.98% year-over-year to -$378000.0 in Q2 2026; TTM through Jun 2026 was -$2.7 million, a 80.66% increase from a year earlier, with the FY2025 full-year figure at -$4.3 million, down 192.62% from the prior year.
• Net Cash Flow was -$378000.0 for Q2 2026 at Vivos Therapeutics, down from $81000.0 in the prior quarter.
• Over five years, Net Cash Flow peaked at $4.3 million in Q2 2024 and troughed at -$9.4 million in Q2 2025.
• A 5-year average of -$1.9 million and a median of -$1.2 million in 2025 frame the typical range for Net Cash Flow.
• Across the five-year window, Net Cash Flow soared 237.03% in 2024 and tumbled 9409.09% in 2025, its largest moves.
• Over 5 years, Net Cash Flow stood at -$3.2 million in 2022, then surged by 120.53% to $657000.0 in 2023, then slumped by 101.67% to -$11000.0 in 2024, then plunged by 9409.09% to -$1.0 million in 2025, then surged by 63.86% to -$378000.0 in 2026.
• The last three Net Cash Flow figures came in at -$378000.0 (Q2 2026), $81000.0 (Q1 2026), and -$1.0 million (Q4 2025), per Business Quant data.